STOCK TITAN
  1. Home
  2. Sec-filings
  3. MED
  4. [Form 4] MEDIFAST INC Insider Trading Activity

Medifast (NYSE: MED) director adds 4,329 shares via funds

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

MEDIFAST INC (MED) director Kiai Parsa reported indirect open-market purchases of MED common stock on August 24, 2026. Entities associated with him bought 4,329 shares in total at an average price of $11.9996 per share, with actual prices ranging from $11.99 to $12. The purchases were made through Steamboat Capital-related funds, and Parsa may be deemed to have a pecuniary interest in those shares, while disclaiming beneficial ownership beyond that interest.

Positive

  • None.

Negative

  • None.
Insider Kiai Parsa
Role Director
Bought 4,329 shs ($52K)
Type Security Shares Price Value
Purchase Common Stock F1, F3, F4 4,211 $11.9996 $51K
Purchase Common Stock F2, F3, F4 118 $11.9996 $1K
Holdings After Transaction: Common Stock — 19,095 shares (Indirect, Notes)
Footnotes (4)
  1. F1. Ownership of Steamboat Capital Partners Master Fund, LP (Master) which has delegated investment discretion to Steamboat Capital Partners, LLC (IA).
  2. F2. Ownership of Steamboat Capital Partners II, LP (II).
  3. F3. Steamboat Capital Partners GP, LLC (GP) is general partner of, and entitled to receive a performance allocation from, each of Master and II. Parsa Kiai ("Kiai") is the Managing Member of GP and IA. Accordingly, Kiai may be deemed to have a pecuniary interest in the shares owned by Master and II. Kiai disclaims beneficial ownership of securities reported hereon except to the extent of his pecuniary interest therein.
  4. F4. This is an average price. Actual prices paid for the shares purchased on 8/24/26 and reported on this line range from $11.99 to $12. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Total shares purchased 4,329 shares of Common Stock Indirect open-market or private purchases on August 24, 2026
Average purchase price $11.9996 per share Average price for shares purchased on August 24, 2026
Price range $11.99 to $12 per share Actual prices paid for purchases on August 24, 2026
Shares purchased for Master Fund 4,211 shares Owned by Steamboat Capital Partners Master Fund, LP
Shares purchased for Fund II 118 shares Owned by Steamboat Capital Partners II, LP
pecuniary interest financial
"Kiai may be deemed to have a pecuniary interest in the shares"
indirect financial
"The reported MED holdings are indirect. The shares are owned by funds"
performance allocation financial
"GP is general partner of, and entitled to receive a performance allocation"

FAQ

What insider transaction did MED (MEDIFAST INC) report for Kiai Parsa?
MED reported that director Kiai Parsa, through related investment entities, indirectly purchased 4,329 shares of MED common stock on August 24, 2026 in open-market or private transactions at an average price of about $11.9996 per share.

At what price were the MED shares bought in Kiai Parsa’s August 24, 2026 Form 4?
The filing states an average purchase price of $11.9996 per share for the MED common stock, with actual prices on August 24, 2026 ranging from $11.99 to $12 per share for the reported transactions.

How many MED shares did entities associated with Kiai Parsa acquire?
Entities associated with Kiai Parsa acquired a total of 4,329 shares of MEDIFAST INC common stock, consisting of 4,211 shares for Steamboat Capital Partners Master Fund, LP and 118 shares for Steamboat Capital Partners II, LP.

Is Kiai Parsa’s ownership in MED direct or indirect in this Form 4?
The reported MED holdings are indirect. The shares are owned by funds (Master and II) managed by Steamboat Capital entities, and Kiai Parsa is the managing member. He may be deemed to have a pecuniary interest and disclaims beneficial ownership beyond that interest.

Were Kiai Parsa’s MED purchases under a Rule 10b5-1 trading plan?
The Form 4 indicates that the Rule 10b5‑1 checkbox is not affirmed (set to false), and the footnotes describe the transactions and ownership structure but do not state that these purchases were made pursuant to a Rule 10b5‑1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kiai Parsa
(Last)(First)(Middle)
24 MAPLE AVE
(Street)
RYE NEW YORK 10580
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MEDIFAST INC [ MED ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/24/2026P4,211A$11.9996665,517INotes(1)(3)(4)
Common Stock08/24/2026P118A$11.999619,095INotes(2)(3)(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Ownership of Steamboat Capital Partners Master Fund, LP (Master) which has delegated investment discretion to Steamboat Capital Partners, LLC (IA).
2. Ownership of Steamboat Capital Partners II, LP (II).
3. Steamboat Capital Partners GP, LLC (GP) is general partner of, and entitled to receive a performance allocation from, each of Master and II. Parsa Kiai ("Kiai") is the Managing Member of GP and IA. Accordingly, Kiai may be deemed to have a pecuniary interest in the shares owned by Master and II. Kiai disclaims beneficial ownership of securities reported hereon except to the extent of his pecuniary interest therein.
4. This is an average price. Actual prices paid for the shares purchased on 8/24/26 and reported on this line range from $11.99 to $12. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
/s/ Parsa Kiai08/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR